Is Dyadic International, Inc. (NASDAQ:DYAI) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Dyadic International, Inc. at current levels.
A $28M microcap with a fungal protein platform that could reprice 5x if even one Dapibus customer scales commercially in 2026-2027.
Where DYAI is headed
Dyadic in mid-2028 looks nothing like the lab-services curiosity trading at 78 cents today. The pivot away from pharmaceutical platform licensing toward Dapibus, the non-pharma protein production system aimed at food, nutrition, life sciences reagents and bio-industrial enzymes, is the whole game now. Revenue grew 182% on a tiny base because actual customers are paying for actual protein. That is the bridge from 'interesting science' to 'commercial supplier of recombinant proteins at fungal-fermentation economics'. The destination is a business doing $20-30M in annual revenue by 2028, mostly from Dapibus product sales plus milestone payments from the Rubic One Health and Phibro Animal Health livestock vaccine programs, at gross margins climbing through 40% as the mix shifts from R&D services to repeat-order proteins.
Read the full Compass Direction on DYAI
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $0.78).
See the full DYAI analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Dyadic International, Inc. (NASDAQ:DYAI) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Dyadic International, Inc. at current levels. A $28M microcap with a fungal protein platform that could reprice 5x if even one Dapibus customer scales commercially in 2026-2027.
What is DYAI's Compass Score?
Dyadic International, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for DYAI?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the DYAI page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.